Investigating Study Drug RO4786967 in Participants with Idopathic Parkinson's Disease.

Parkinson’s disease is a chronic disease of the nervous system that gets worse over time. Available treatments cannot stop or slow down the worsening over time. Some evidence suggests that people with Parkinson’s disease may have more inflammation in the brain. This is thought to be one of the reasons why people get Parkinson's disease and why it worsens over time. A key part of the inflammation in the brain is a protein called NLRP3. RO748967 blocks NLRP3, which might lower the inflammation in the brain. The purpose of this study is to investigate what happens to RO7486967 once it is in the body, what RO7486967 does to the body, and to compare the effects (good or bad) of RO7486967 versus placebo on the inflammation in the brain and on Parkinson’s disease symptoms. In this study, participants will get either RO7486967 or placebo. Approximately 48 to 72 people with Parkinson’s disease will take part in this study.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research, Parkinson's Disease
• Age: 18 years - 99 years
• Gender: All